

Soluble HLA-G changes in maternal blood serum during the progression of labor

Anna KNAFEL¹, Pawel BASTA¹, Kazimierz PITYNSKI¹, Pawel MACH¹,
Wieslawa BEDNAREK², Marek KLIMEK³, Jerzy ZIETEK⁴, Kszysztof ZAJAC¹,
Lukasz DANCEWICZ¹, Mirosława IWANIEC¹, Antoni BASTA¹, Lukasz WICHEREK¹

1. Department of Gynecology and Oncology, Jagiellonian University, 23 Kopernika Str, 31-501 Krakow, Poland;
2. Department of Gynecology and Oncology, Medical University Lublin, Poland;
3. Faculty of Public Health of the Jagiellonian University, Krakow, Poland.
4. Department of Gynecology and Obstetrics, Slaski Medical University, Katowice, Poland

Correspondence to: Lukasz Wicherek M.D., Ph.D.;
Gynecology, Obstetrics and Oncology Department of the Jagiellonian University,
23 Kopernika Str, 31-501 Krakow, Poland;
TEL. +48 12 424 85 84; FAX: +48 12 424 85 84; E-MAIL: mowicher@cyf-kr.edu.pl

Submitted: 2008-10-21 *Accepted:* 2008-10-30 *Published online:* 2009-03-03

Key words: sHLA-G; labor; Cesarean section; preterm labor; immune tolerance

Neuroendocrinol Lett 2009;30(1):67-73 PMID: 19300382 NEL300109A18 © 2008 Neuroendocrinology Letters • www.nel.edu

Abstract

BACKGROUND: The expression of the HLA-G antigen from implantation toward term is crucial for the growth of a semiallogenic fetus as it shields this fetus from the maternal cytotoxic response. Little is known, however, about the potential role of soluble HLA-G isoforms during delivery. The initiation of labor is associated with a complex molecular response leading to a brief activation of the maternal immune system with an accompanying capacity to restrict this activation, and HLA-G seems to be an important factor in enabling the proper immune response at the maternal fetal interface.

METHODS: In our study the levels of soluble HLA-G concentration were evaluated in the blood serum samples obtained from 47 pregnant women who either underwent cesarean sections or delivered vaginally. The patients were divided into three subgroups according to the progression of labor at the time of the cesarean or, in cases of vaginal delivery, according to the duration of the pregnancy.

RESULTS: We have observed that the progression of labor is associated with a continuous increase in the sHLA-G plasma level. The sHLA-G levels were statistically significantly higher in the blood sera obtained from the women in advanced labor than from the women who were at the beginning of labor.

CONCLUSION: The changes in sHLA-G concentration levels observed during the stages of labor may indicate that this isoform participates in maintaining reproductive tract homeostasis.

INTRODUCTION

HLA-G is a non-classical human leukocyte antigen of Class Ib. It plays an important role in setting up and maintaining the immune tolerance that is achieved by the inhibition of immunocompetent cells [1]. As a result of an alternative splicing of a

primary HLA-G transcript, seven isoforms of this antigen are generated. Four of them (G1-G4) are bound to a cell surface, while three others (G5-G7) that lack the exons for cytoplasmic and transmembrane domain constitute the soluble isoforms [2,3]. The latter may be either secreted (HLA-G5) or proteolytically cleaved from the cell surface

(sHLA-G1). The function of the HLA-G molecule is firstly related to the fetal–maternal tolerance where its expression by cytotrophoblast prevents the fetus from attack by maternal natural killer (NK) cells [4]. As the non-classical HLA Class I molecule, HLA-G exerts its function by binding to inhibitory receptors—such as the leukocyte-inhibitory receptors LILRB1/ILT-2/CD85j, ILT-4/LILRB2/CD85d, and KIR2DL4 [5,6]—this interaction leads to the inhibition of the following processes: CD4+ T cell proliferation [5,7], the cytotoxic activity of CTL and NK cells [5,8,9], dendritic cell maturation [10], and the cell cycle progression of alloreactive T cells [11]. Furthermore, through the mechanism known as “trogoctosis” [12], HLA-G upregulates its own receptors [13] and shifts the cytokine TH1/Th2 balance toward Th2 [14,15].

As with the membrane-bound HLA-G, the soluble isoforms exhibit the immunosuppressive activities [5] that are characteristic of HLA-G1 and the secreted HLA-G5 proteins. In addition, the soluble HLA-G isoforms (both shed HLA-G1 and HLA-G5) can induce Fas-dependent apoptosis of activated CD8+ T and NK cells [16,17] and can also inhibit angiogenesis by their interaction with the CD160/BY55 receptor [18]. The suppressive functions of soluble HLA-G isoforms may be seen not only at the local site of their expression but also – unlike their membrane-bound counterparts – at distant sites throughout the peripheral circulation.

In pregnancy, it has been found that villous cytotrophoblast cells produce just one HLA-G isoform, HLA-G5 [19]. In contrast, the extravillous cytotrophoblast that is close to the decidua, not only expresses the membrane HLA-G isoform, HLA-G1, but also possibly a second isoform, HLA-G2 [19,20]. Although HLA-G is produced by these cells throughout pregnancy, its expression is the highest in the first trimester and declines toward term. Soluble HLA-G isoform has been detected in the supernatant culture media from *in vitro* cultured embryos [21] and in maternal and cord blood [20] as well as in amniotic fluid. [22,23]

The function of HLA-G and its soluble isoform in pregnancy has already been established in many studies. Expression of the HLA-G antigen, from implantation to term, is crucial for the growth of a semiallogenic fetus as it shields this fetus from the maternal cytotoxic response [19]. Disturbances in HLA-G expression are therefore thought to be associated with the development of various obstetric complications, such as, preeclampsia, placental abruption, or IUGR [24–26]. Little is known, however, about the potential role of HLA-G isoforms during delivery. The initiation of labor is associated not only with an increase in endocrine signals from the fetal adrenals, but also with a complex molecular response leading to a brief activation of the maternal immune system with an accompanying capacity to restrict this very activation [27–44], and HLA-G seems to be an important factor enabling the proper immune response at the maternal-fetal interface. In order to verify this

hypothesis we have aimed in this study to measure the concentration level of the soluble HLA-G isoform with respect to the progression of labor at term.

2. MATERIALS AND METHODS

2.1 Patients

The blood serum samples evaluated in our study were obtained from 47 pregnant women who either underwent cesarean sections or delivered vaginally. The women included in our study were selected from those who delivered in 2007 at the Department of Gynecology, Obstetrics and Oncology of the Jagiellonian University, Krakow, Poland. The patients were divided into three subgroups either according to the progression of labor at the time of the cesarean or in cases of vaginal delivery, according to the duration of pregnancy. The following groups were distinguished: Group One consisted of 24 women, 12 of whom underwent elective cesarean section without labor (i.e., with cervical external os closed), and 12 women on whom cesarean sections were performed after the spontaneous beginning of labor (i.e., whose cervical dilation was less than 3 cm at the time of the cesarean). Group Two comprised 7 women on whom cesarean sections were performed during advanced labor (i.e., whose cervical dilation was more than 3 cm at the time of the cesarean) and 9 women who experienced spontaneous, uncomplicated vaginal delivery at term. Finally, Group Three consisted of 7 women with preterm delivery (25–36 wks). Preterm delivery at the time of diagnosis was accompanied by uncontrollable progressive cervical dilation and pathological findings in the CTG reading indicating fetal stress or the preterm rupture of membranes. The patients included in these subgroups delivered vaginally. The various indications for cesarean section were as follows: fetal distress syndrome, malpresentation, uterine myoma, previous cesarean delivery, and fetal heart defect. We have also used this division in our recent studies concerning the regulation of immune system activity during labor [27,28,35,45]. Patients with multiple pregnancies or existing complications of pregnancy (such as hypertension and diabetes mellitus) were excluded from this study, as were cases of fetal demise. Additionally, patients with intra-amniotic infection, as confirmed by histopathological examination of the fetal membranes and chorionic plate or other symptoms of intrauterine infections, were excluded from the study.

The patient's consent was obtained in each case. Prior to the present study we also obtained the approval of the Jagiellonian University Ethical Committee for our research program (KBET/135/B/2007).

2.2. ELISA

The blood was collected in a serum collection tube prior to surgery in patients on whom cesarean sections were performed and, in cases of patients who delivered

Table 1. Clinical characteristic of patients

Variables	Group I (n=24)	Group II (n=16)	Group III (n=7)	p-value
Maternal age (median, IQR)	30 (7)	30 (6)	30.5 (8)	0.76
Parity (median, IQR)	2 (1.5)	1 (2)	2 (2)	0.33
Gestational age (median, IQR)	38 (2)	39 (2)	33 (6)	<0.01
Newborn mass (median, IQR)	3145 (580)	3220 (560)	1920 (1100)	0.02
Newborn length (median, IQR)	53 (5)	54 (6)	47 (8)	0.01
Apgar score (median, IQR)	10 (1.5)	10 (0.0)	7 (2)	<0.01

IQR – intraquartile range

vaginally, during the active phase of stage I of labor. A clot was allowed to form at room temperature for 30–60 minutes. The tube was placed on ice for 30 minutes in order to contract the clot. The serum samples were then centrifuged at 3000 xg for 10 minutes at room temperature. The supernatants 1.0–2.0 ml were collected and stored at –80°C. The soluble human leukocyte antigen-G (sHLA-G) was determined using the sHLA-G sandwich ELISA kit (BioVendor-Exibo, Czech Republic). Stated briefly, the blood plasma samples were diluted twice and incubated for 1 hour in the 96-well microplate pre-coated with the monoclonal anti-sHLA-G antibodies. Following incubation the wells were washed and filled with the monoclonal anti-human beta-2-microglobulin antibodies labeled with horseradish peroxidase. After an additional 1 hour of incubation, the wells were again washed and the color reaction was developed using tetramethyl benzidine (TMB) substrate. The absorbance values were measured at 450 nm on a microplate reader followed by calculation of the sHLA-G concentrations. Finally, the assay was calibrated using a set of sHLA-G standards provided by the producer of the kit.

2.3 Statistical analysis

The distribution of variables in the study groups of women checked with the use of the Shapiro-Wilk test showed that each of them was different from normal. The statistical significance between the groups was determined by the Kruskal-Wallis analysis of variance (ANOVA) test. The Mann-Whitney U test was then used as applicable.

RESULTS

3.1 Clinical comparison of analyzed groups of patients

Since the indications for performing a cesarean section vary, it would seem important to compare the parameters characterizing the course of pregnancy and labor in the groups of patients considered (Table 1).

We did not observe any statistically significant differences in maternal clinical parameters among the groups examined. Since the examined group of patients included those with preterm delivery, the differences

in clinical parameters such as gestational age, newborn mass, newborn length, and Apgar score are understood from a clinical point of view. This profile of clinical parameters characterizing the course of pregnancy enabled us to compare the respective sHLA-G blood serum concentration levels in these groups.

3.1 Soluble sHLA-G levels in maternal blood serum with respect to the progression of labor

During labor at term, the blood serum sHLA-G concentration level significantly increases. The levels of sHLA-G blood serum concentration in group I ranged from 0 to 26.6 U/ml (32% positive cases); in group II they ranged from 0 to 59.18 U/ml (75% positive cases), and in group III from 4.42 to 70.41 U/ml (all cases were positive). The highest level of sHLA-G concentration was observed in group III, that is, in the women with preterm delivery. The sHLA-G levels were statistically significantly higher in the blood sera obtained from the women in advanced labor than in the sera from those women who were at the beginning of labor (Figure 1).

DISCUSSION

In the present study we have focused on the maternal sHLA-G plasma levels during the course of labor, and we have observed that the progression of labor is associated with a continuous increase in the sHLA-G plasma level. To our knowledge (based on a literature search in PubMed), this is the first investigation to concentrate on the sHLA-G level in patients who delivered by cesarean at term according to the progression of labor at the time of the procedure.

During pregnancy, the HLA-G antigen is expressed in high levels by an extravillous trophoblast [19,46]. HLA-G protein is also present in maternal compartment-decidua where its expression has been found to be dependent on hormones, mainly progesterone and certain cytokines [47]. The soluble isoform-sHLA-G is present in villous cytotrophoblast [48,49] and in maternal and fetal circulation as well as in the amniotic fluid [19,22,23]. In the maternal plasma, the sHLA-G level is the highest during the first trimester of pregnancy




Figure 1. The analysis of the maternal blood serum concentration level according to the progression of labor at the time of the cesarean or, in cases of vaginal delivery, according to the duration of pregnancy. Group One consisted of both women who underwent elective cesarean sections without labor and women on whom cesarean sections were performed after the spontaneous beginning of labor. Group Two comprised both women who underwent cesarean sections during advanced labor and women who experienced spontaneous, uncomplicated vaginal delivery at term. Group Three consisted of women with preterm delivery.

and then declines as term approaches. Similar changes in expression throughout pregnancy have been noted for a membrane-bound HLA-G isoform [22].

Expression of HLA-G at the feto-maternal interface is thought to protect the semiallogenic fetus from being rejected by acting as a barrier to maternal allo-immune competent cells. Membrane-bound HLA-G isoforms inhibit uterine natural killer (NK) cell function while soluble proteins modulate cytokine production by blood cells [14,15] and affect cytotoxic T lymphocytes by diverting their cycle to a programmed death [5,8,16,17]. In contrast, T helper lymphocytes are programmed into tolerant ones [12]. It has been suggested, based on the studies of embryo cultures, that HLA-G secretion is necessary for successful implantation [50]. Impaired expression of the HLA-G antigen by trophoblast cells as well as its soluble isoform is associated with obstetric complications. Decreased expression of HLA-G has been noted in recurrent pregnancy losses [51]. Moreover, compared to the levels found in normal pregnancy, the plasma levels of sHLA-G in cases of placental abruption and preeclampsia are low. [24–26, 52,53]. Furthermore, a lower level early in the course of pregnancy may predict the occurrence of preeclampsia later on [53]. In our study, the highest maternal blood serum sHLA-G concentration level was observed in patients with preterm labor. These results correlate well with the findings of Steinborn *et al.* who have reported that the level of sHLA-G in women with uncontrollable preterm labor as well as in the patients with HELLP

syndrome is significantly increased [24,25]. The latter syndrome is also associated with a higher concentration level of sHLA-DR antigens in maternal circulation [54] than had previously been documented for the state of acute graft rejection after transplantation. The authors have therefore suggested that the pathomechanism of these complications may resemble that of acute rejection where excessive allogenic reaction is key.

Despite reports about how HLA-G isoforms function throughout pregnancy and in pregnancy-related disorders, they have yet to be evaluated during the course of labor. In one of the studies, Steinborn *et al.* evaluated pregnancies at term, and a significant difference between the mode of delivery and the level of sHLA-G in maternal circulation was not found. This would suggest that the status of labor has no influence on the content of sHLA-G in the maternal plasma; however, the authors mentioned did not evaluate sHLA-G according to the particular stage of labor [24].

So far it has been known that the beginning of parturition is dependent upon signals from the fetal adrenal glands; more recently, a change in the pattern of cytokine concentration (IL-6, IL-8) [33] as well as an increase in the cytotoxic activity of the immune cells has also been identified [30,31,35]. Our previous reports have shown that parturition is a dynamic process accompanied by particular immunological alterations; for example, alterations in the infiltration and activity of CD3+ and CD56+ cells in decidua, in immunoreactivity, and in the concentration of inhibitory proteins [27,28,32,35,42].

Steinborn *et al.* have observed that spontaneous labor at term is accompanied by a significantly elevated release of IL-6 from fetal monocytes that has not been found in cases of induced term or preterm delivery. It has been suggested that the fetal phagocyte activation was due to the presence of the maternal lymphocyte-T alloantigen stimulation that crosses the placental barrier at the end of pregnancy [29].

The serum level of sHLA-G is higher in pregnant women than in non-pregnant women [22,23]. Soluble HLA-G concentration peaks in the first trimester and then decreases until term. As has been shown to be the case with the level of sHLA-G concentration in maternal blood during pregnancy, sHLA-G in amniotic fluid significantly decreases from the second trimester until term [22]. Moreover, while a significant correlation between the sHLA-G concentration levels in maternal and fetal blood has been found, no such correlation between the levels of concentration in the maternal blood and amniotic fluid was observed [22]. The varied distribution of sHLA-G in body fluids during pregnancy as well as the changes in the protein concentration over the course of labor may suggest that the protein has a different origin. For this reason we can speculate that during delivery sHLA-G may be derived not only from trophoblasts, but also from the activated immune cells of both mother and fetus. Alegre *et al.* have discovered that maternal monocytes as well as DCs express sHLA-G in pregnancy. This suggests that the contribution of maternal APCs to the circulating pool of HLA-G protein probably becomes more important as pregnancy advances [55]. Furthermore, the secretion of sHLA-G was increased by IFN-gamma [55]; this finding agreed with previous reports where the role of cytokines in regulating such antigen expression has been documented [56–58]. Moreover, IL-10, which is also produced by cytotrophoblast cells, was seen to increase HLA-G expression. This cytokine plays an important role in maintaining the immune tolerance level crucial for a successful pregnancy. Additionally, it has been observed that the level of IL-10 was lower in women suffering from recurrent pregnancy losses [59]; this is similar to what has been reported for HLA-G [51]

In our recent study, we have seen that this growth of maternal immune cell activity at the beginning of labor is associated with the subsequent growth of the expression of a decidual protein, such as RCAS1, and that its soluble form in maternal blood serum inhibits maternal cytotoxic cell activity [28,32,42,45,60–65]. In the present study we have found that sHLA-G concentration rises with the progression of labor in a way comparable to the increase in the blood serum level of RCAS1 that takes place as labor advances. Moreover, the sHLA-G level was significantly higher in advanced labor than at the beginning of delivery. The changes in sHLA-G concentration levels observed during the various stages

of labor may indicate that it participates in maintaining reproductive tract homeostasis.

6. ACKNOWLEDGMENTS

We wish to thank Professors J. Kotarski, A. Skret and J. Sikora for their advice, helpful discussions, and friendly words of support. I would also like to thank Christine Maisto and Drs. Tomasz Banas and Pawel Mak for their assistance. This work was funded by the Polish Ministry of Science, Grant Number: Nr 0888/B/P01/2008/35.

REFERENCES

- 1 Rouas-Freiss N, Naji A, Durrbach A, Carosella ED. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. *Transplantation*. 2007; **84**(1 Suppl): S21–5.
- 2 Carosella ED, Moreau P, Le Maout J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. *Adv Immunol* 2003; **81**: 199–252.
- 3 Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. *Proc Natl Acad Sci U S A* 1992; **89**(9): 3947–51.
- 4 Rouas-Freiss N, Goncalves RM, Menier C, Dausset J and Carosella ED (1997a) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytotoxicity. *Proc Natl Acad Sci USA* 1997; **94**(21): 11520–11525.
- 5 Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: Are they clinically relevant? *Semin Cancer Biol*. 2007; **17**(6): 469–79.
- 6 Colonna M, Navarro F, Bellón T, Llano M, García P, Samaridis J, Angman L, Cella M, López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. *J Exp Med*. 1997; **186**(11): 1809–18.
- 7 Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. *J Reprod Immunol*. 2000; **48**(1): 17–26.
- 8 Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. *Int Immunol*. 1999; **11**(8): 1351–6.
- 9 Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? *Proc Natl Acad Sci U S A*. 1997; **94**(10): 5249–54.
- 10 Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. *Eur J Immunol*. 2005; **35**(4): 1133–42.
- 11 Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, Carosella ED, Charpentier B, Durrbach A. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. *J Immunol*. 2006; **176**(3): 1331–9.
- 12 LeMaout J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. *Blood*. 2007; **109**(5): 2040–8.
- 13 LeMaout J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. *FASEB J*. 2005; **19**(6): 662–4.
- 14 Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. *Immunology*. 2000; **101**(2): 191–200.
- 15 Kanai T, Fujii T, Kozuma S, Yamashita T, Miki A, Kikuchi A, Taketani Y. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. *Mol Hum Reprod*. 2001; **7**(2): 195–200.

- 16 Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. *Eur J Immunol.* 2003; **33**(1): 125–34.
- 17 Solier C, Aguerre-Girr M, Lenfant F, Campan A, Berrebi A, Rebmann V, Grosse-Wilde H, Le Bouteiller P. Secretion of proapoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. *Eur J Immunol.* 2002; **32**(12): 3576–86.
- 18 Le Bouteiller P, Fons P, Heralut JP, Bono F, Chabot S, Cartwright JE, Bensussan A. Soluble HLA-G and control of angiogenesis. *J Reprod Immunol* 2007; **76**(1–2): 17–22.
- 19 Hunt JS, Langat DK, McIntire RH, Morales PJ. The role of HLA-G in human pregnancy. *Reprod Biol Endocrinol.* 2006; **4**(Suppl 1): S10
- 20 Morales PJ, Pace JL, Platt JS, Phillips TA, Morgan K, Fazleabas AT, Hunt JS. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. *J Immunol.* 2003 **171**(11): 6215–24.
- 21 Noci I, Fuzzi B, Rizzo R, Melchiorri L, Criscuoli L, Dabizzi S, Biagiotti R, Pellegrini S, Menicucci A, Baricordi OR. Embryonic soluble HLA-G as a marker of developmental potential in embryos. *Hum Reprod.* 2005; **20**(1): 138–46.
- 22 Hackmon R, Hallak M, Krup M, Weitzman D, Sheiner E, Kaplan B, Weinstein Y. HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy. *Fetal Diagn Ther.* 2004; **19**(5): 404–9.
- 23 Rebmann V, Pfeiffer K, Pässler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. *Tissue Antigens.* 1999; **53**(1): 14–22.
- 24 Steinborn A, Rebmann V, Scharf A, Sohn C, Grosse-Wilde H. Placental abruption is associated with decreased maternal plasma levels of soluble HLA-G. *J Clin Immunol.* 2003; **23**(4): 307–14.
- 25 Steinborn A, Varkonyi T, Scharf A, Bahlmann F, Klee A, Sohn C. Early detection of decreased soluble HLA-G levels in the maternal circulation predicts the occurrence of preeclampsia and intrauterine growth retardation during further course of pregnancy. *Am J Reprod Immunol.* 2007; **57**(4): 277–86.
- 26 Hackmon R, Koifman A, Hyodo H, Glickman H, Sheiner E, Geraghty DE. Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia. *Am J Obstet Gynecol.* 2007; **197**(3): 255.e1–5.
- 27 Galazka K, Pitynski K, Skret-Magierlo J, Mach P, Knafel A, Sikora J, Niemiec T, Dobrogowski J, Basta A, Wicherek L. The increase in metallothionein and ectopic decidual immunoreactivity with respect to the progression of labor at term and the lack of analogical changes in placental abruption. *Am J Reprod Immunol.* 2008; **60**(3): 204–13.
- 28 Wicherek L, Basta P, Galazka K, Mak P, Dancewicz L, Kalinka J. RCAS1 decidual immunoreactivity and RCAS1 serum level during cesarean section with respect to the progression of labor. *Am J Reprod Immunol.* 2008; **59**(2): 152–8.
- 29 Steinborn A, Sohn C, Sayehli C, Baudendistel A, Hüwelmeier D, Solbach C, Schmitt E, Kaufmann M. Spontaneous labour at term is associated with fetal monocyte activation. *Clin Exp Immunol.* 1999; **117**(1): 147–52.
- 30 Szekeres-Bartho J, Varga P, Pacsa AS. Immunologic factors contributing to the initiation of labor—lymphocyte reactivity in term labor and threatened preterm delivery. *Am J Obstet Gynecol* 1986; **155**(1): 108–112.
- 31 Abadia-Molina AC, Ruiz C, Montes MJ, King A, Loke YW, Olivares EG. Immune phenotype and cytotoxic activity of lymphocytes from human term decidua against trophoblast. *J Reprod Immunol* 1996; **31**(1–2): 109–123.
- 32 Wicherek L, Klimek M, Dutsch-Wicherek M. The level of maternal immune tolerance and fetal maturity. *Neuro Endocrinol Lett* 2005; **26**(5): 561–566.
- 33 Osmer RG, Blaser J, Kuhn W, Tschesche H. Interleukin-8 synthesis and the onset of labor. *Obstet Gynecol* 1995; **86**(2): 223–229.
- 34 Galazka K, Wicherek L, Sikora J, Czekirowski A, Banas T, Bednarek W, Obrzut B, Blecharz P, Reron A, Kalinka J. RCAS1 Decidual Immunoreactivity during Stillbirth: Immune Cell Presence and Activity. *Am J Reprod Immunol* 2008; **60**(6): 513–522.
- 35 Wicherek L, Galazka K. The possible correlation between the patient's immune tolerance level during cesarean section and the incidence of subsequent emergency peripartum hysterectomy. *Clin Dev Immunol* 2007; 2007: 63596 (doi 10.1155/2007/63596).
- 36 Smith R, Nicholson RC. Corticotrophin releasing hormone and the timing of birth. *Front Biosci* 2007; **12**: 912–918.
- 37 Olson DM, Ammann C. Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour. *Front Biosci* 2007; **12**: 1329–1343.
- 38 Ugur Y, Cakar AN, Beksac MS, Dagdeviren A. Activation Antigens during the Proliferative and Secretory Phases of Endometrium and Early-Pregnancy Decidua. *Gynecol Obstet Invest* 2006; **62**(2): 66–74.
- 39 Al-Asmakh M, Race H, Tan S, Sullivan MH. The effects of oxygen concentration on in vitro output of prostaglandin E2 and interleukin-6 from human fetal membranes. *Mol Hum Reprod* 2007; **13**(3): 197–201.
- 40 Sooranna SR, Grigsby PL, Engineer N, Liang Z, Sun K, Myatt L, Johnson MR. Myometrial prostaglandin E2 synthetic enzyme mRNA expression: spatial and temporal variations with pregnancy and labour. *Mol Hum Reprod* 2006; **12**(10): 625–31.
- 41 Weiss A, Goldman S, Shalev E. The matrix metalloproteinases (MMPs) in the decidua and fetal membranes. *Front Biosci* 2007; **12**: 649–659.
- 42 Wicherek L. The role of the endometrium in the regulation of immune cell activity. *Front Biosci* 2008; **13**: 1018–1035.
- 43 Dutsch-Wicherek M, Sikora J, Tomaszewska R. The possible biological role of metallothionein in apoptosis. *Front Biosci* 2008; **13**: 4029–4038;
- 44 Popiela TJ, Klimek M, Wicherek L, Dutsch-Wicherek M, Galazka K, Rudnicka-Sosin L. The characterization of the exposure to immune mediated apoptosis and the regulation of immune cytotoxic activity in the environment of a neoplasm and in decidua. *Neuro Endocrinol Lett* 2006; **27**(6): 779–785.
- 45 Skret-Magierlo J, Wicherek L, Basta P, Galazka K, Sikora J, Wilk M, Fudali L, Skret A. RCAS1 Decidual Immunoreactivity during Cesarean Section in Scar Deciduoisis: Immune Cell Presence and Activity. *Gynecol Obstet Invest* 2008; **65**(3): 187–194
- 46 Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars RA. A class I antigen, HLA-G, expressed in human trophoblasts. *Science.* 1990; **248** (4952): 220–3.
- 47 Blanco O, Tirado I, Muñoz-Fernández R, Abadía-Molina AC, García-Pacheco JM, Peña J, Olivares EG. Human decidual stromal cells express HLA-G: Effects of cytokines and decidualization. *Hum Reprod.* 2008; **23**(1): 144–52.
- 48 Le Bouteiller P. Human villous trophoblast and the lack of intron 4-retaining soluble HLA-G secretion: beware of possible methodological biases. *Mol Hum Reprod.* 2005; **11**: 711–3.
- 49 Hunt JS. Stranger in a strange land. *Immunol Rev.* 2006 Oct; **213**: 36–47.
- 50 Yao YQ, Barlow DH, Sargent IL. Differential expression of alternatively spliced transcripts of HLA-G in human preimplantation embryos and inner cell masses. *J Immunol.* 2005; **175**(12): 8379–85.
- 51 Pfeiffer KA, Fimmers R, Engels G, van der Ven H, van der Ven K. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. *Mol Hum Reprod.* 2001; **7**(4): 373–8
- 52 Yie SM, Li LH, Li YM, Librach C. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. *Am J Obstet Gynecol.* 2004; **191**(2): 525–9.
- 53 Yie SM, Taylor RN, Librach C. Low plasma HLA-G protein concentrations in early gestation indicate the development of preeclampsia later in pregnancy. *Am J Obstet Gynecol.* 2005; **193**(1): 204–8.
- 54 Filaci G, Contini P, Brenzi S, Lanza L, Scudeletti M, Indiveri F, Puppo F. Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. *Tissue Antigens.* 1995; **46**(2): 117–23.
- 55 Alegre E, Díaz-Lagares A, Lemaout J, López-Moratalla N, Carosella ED, González A. Maternal antigen presenting cells are a source of plasmatic HLA-G during pregnancy: longitudinal study during pregnancy. *Hum Immunol.* 2007; **68**(8): 661–7

- 56 Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. *J Immunol.* 1996; **156**(11): 4224–31.
- 57 Lefebvre S, Moreau P, Guiard V, Ibrahim EC, Adrian-Cabestre F, Menier C, Dausset J, Carosella ED, Paul P. Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. *J Reprod Immunol.* 1999 ; **43**(2): 213–24.
- 58 Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. *Int Immunol.* 1999; **11**(5): 803–11.
- 59 Chaouat G, Assal Meliani A, Martal J, Raghupathy R, Elliot J, Mosmann T, Wegmann T. G. IL-10 prevents naturally occurring fetal loss in the CBAxDBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by *in vivo* injection of IFN-tau. *J. Immunol.* 1995; **154**(9): 4261–8.
- 60 Wicherek L, Galazka K, Lazar A: RCAS1 Decidual Immunoreactivity During Placental Abruption: Immune Cell Presence and Activity. *Am J Reprod Immunol* 2007; **58**(1): 46–55.
- 61 Wicherek L, Basta P, Sikora J, Galazka K, Rytlewski K, Grabiec M, Lazar A, Kalinka J. RCAS1 decidual immunoreactivity in severe pre-eclampsia: immune cell presence and activity. *Am J Reprod Immunol* 2007; **58**(4): 358–366.
- 62 Wicherek L, Galazka K, Lazar A: The analysis of Metallothionein, RCAS1 immunoreactivity regarding immune cells concentration in endometrium and tubal mucosa in ectopic pregnancy during the course of tubal rupture. *Gynecol Obstet Invest* 2007; **65**(1): 52–61.
- 63 Tskitishvili E, Komoto Y, Kinugasa Y, Kanagawa T, Song M, Mimura K, Tomimatsu T, Kimura T, Shimoya K: Relationship between human tumor-associated antigen RCAS1 and gestational diabetes mellitus. *Am J Reprod Immunol* 2007; **58**(5): 440–446
- 64 Tskitishvili E, Komoto Y, Kinugasa Y, Kanagawa T, Song M, Mimura K, Tomimatsu T, Kimura T, Shimoya K: The human tumor-associated antigen RCAS1 in pregnancies complicated by preeclampsia. *J Reprod Immunol* 2008; **77**(1): 100–8.
- 65 Sonoda K, Miyamoto S, Nakashima M, Wake N: The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. *Front Biosci* 2008; **13**: 1106–1116.